🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06641700
Active, not recruiting Observational

Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.

NCT06641700 · tracked via the Priya Life Science China tracker
Sponsor
Dong Peng
Phase
Observational
Started
2024-10-01
Last updated
2024-10-16

Condition(s) studied

Gastric Cancers

Investigational drug(s) / intervention(s)

diagnosed with gastric cancer

diagnosed with gastric cancer: Pathological biopsy confirmed the diagnosis of gastric cancer.

Study summary

As one of the common malignant tumours worldwide, gastric cancer continues to have a high incidence and mortality rate, especially in Asia. Although a large number of studies have focused on its underlying genetic and lifestyle factors, the specific role of environmental factors in gastric cancer development and progression has not been fully elucidated. Air pollution, a growing environmental problem, and its major components such as PM2.5, PM10, and NO2 have been shown to be closely associated with the occurrence and development of many chronic diseases. Recent studies have gradually revealed the association between air pollution and certain cancer types (e.g., lung cancer), but its relationship with gastric cancer remains relatively unexplored. Against this background, the application of metabolomics provides new perspectives and methods to study the association between gastric cancer and environmental factors. Metabolomics is capable of systematically analysing the metabolite composition and changes in individuals under different environmental exposures, revealing the potential effects of environmental factors, such as air pollution, on individual metabolic functions. By combining air pollution data and metabolomics analysis, investigators can deeply explore the role of environmental factors in the occurrence, development and prognosis of gastric cancer, and thus provide a scientific basis for the development of prevention and treatment strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of gastric cancer confirmed by pathology or cytology; * aged \>18 years; * not received chemotherapy, radiotherapy, targeted therapy or immunotherapy; * post-operative pathological stages other than stage IV, or no liver, lung or other organs as confirmed by CT, MRI, B-ultrasound imaging. Exclusion Criteria: * Patients with systemic diseases such as severe cardiorespiratory insufficiency affecting the choice of treatment regimen; * inappropriate for enrolment as assessed by the investigator; * incomplete clinical data.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality

More Dong Peng trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06641700 on ClinicalTrials.gov ↗ ← All trials in China